About Biofidelity
Biofidelity is a company based in Cambridge (United Kingdom) founded in 2002 by Barney Balmforth and Cameron Frayling. Biofidelity has raised $59.91 million across 4 funding rounds from investors including Agilent, Octopus Ventures and BlueYard Capital. The company has 28 employees as of December 31, 2024. Biofidelity offers products and services including Aspyre®, Aspyre® Lung Reagents, and Enspyre®. Biofidelity operates in a competitive market with competitors including Guardant Health, Foundation Medicine, ArcherDX, Natera and Strand Life Sciences, among others.
- Headquarter Cambridge, United Kingdom
- Employees 28 as on 31 Dec, 2024
- Founders Barney Balmforth, Cameron Frayling
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Biofidelity Ltd
- Date of Incorporation 15 Feb, 2019
- Jurisdiction CAMBRIDGE, ENGLAND
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$59.91 M (USD)
in 4 rounds
-
Latest Funding Round
$24 M (USD), Series B
Apr 03, 2024
-
Investors
Agilent
& 4 more
-
Employee Count
28
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Biofidelity
Biofidelity offers a comprehensive portfolio of products and services, including Aspyre®, Aspyre® Lung Reagents, and Enspyre®.
Technology for simple and reliable cancer biomarker detection.
Reagents supporting genomic testing for lung cancer applications.
Platform for end-to-end cancer patient journey monitoring.
People of Biofidelity
Unlock access to complete
Unlock access to complete
Funding Insights of Biofidelity
Biofidelity has successfully raised a total of $59.91M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $24 million completed in April 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Biofidelity
Biofidelity has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Agilent, Octopus Ventures and BlueYard Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investment and support for founders in technology and health sectors.
|
Locked | Locked | Locked | |
|
BlueYard Capital is engaged in early-stage technology investments.
|
Locked | Locked | Locked | |
|
Early-stage deeptech businesses are supported through venture capital investments.
|
Locked | Locked | Locked |
Investor details for Biofidelity
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Biofidelity
Investment portfolio details for Biofidelity
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Biofidelity
Detailed financials for Biofidelity
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Biofidelity Comparisons
Peer comparison for Biofidelity
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Biofidelity
Biofidelity operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, Foundation Medicine, ArcherDX, Natera and Strand Life Sciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery
|
|
| Locked | Locked | Locked |
Health risks are identified through online genetic and diagnostic testing.
|
Detailed competitors of Biofidelity
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Biofidelity
Complete news archive for Biofidelity
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biofidelity
Biofidelity was founded in 2002 and raised its 1st funding round 17 years after it was founded.
Biofidelity is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Barney Balmforth is the current CEO of Biofidelity. They have also founded this company.
Biofidelity is a funded company, having raised a total of $59.91M across 4 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Biofidelity is 28.
Biofidelity was founded in 2002 in Cambridge, United Kingdom, within the biotechnology sector. Molecular diagnostic assays are developed using proprietary ASPYRE technology. Genetic panels are created for detecting specific cancers, including colorectal, melanoma, head and neck, liver and kidney, and breast. Operations focus on advancing diagnostic tools for oncology applications in a clinical setting.
Biofidelity's top competitors include Guardant Health, Strand Life Sciences and Foundation Medicine.
Biofidelity offers Aspyre®, Aspyre® Lung Reagents, and Enspyre®.
Biofidelity has 5 investors. Key investors include Agilent, Octopus Ventures, BlueYard Capital, Longwall Ventures, and SBI Investment.